Literature DB >> 15064939

Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome.

Maria Van Dyck1, Willem Proesmans.   

Abstract

Five patients with severe hemolytic uremic syndrome (HUS) were followed for 10-18 years. Because of proteinuria, arterial hypertension, and reduced glomerular filtration rates, they received either captopril (n=2) or enalapril (n=3), or both (n=1) for 8-15 years. Blood pressure was normalized and proteinuria reduced in all; glomerular filtration improved in three patients and fell moderately in two. Four of the five patients have reached adult age with body weight and height, blood pressure, and serum creatinine levels within the normal range. At the last evaluation, median proteinuria was 220 mg/24 h (range 0-310) and glomerular filtration rate 56 ml/min per 1.73 m(2)(range 40-127). This long-term study indicates a renoprotective effect of angiotensin-converting enzyme inhibitors in patients with sequelae after HUS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064939     DOI: 10.1007/s00467-004-1451-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  13 in total

Review 1.  Remission of renal disease: recounting the challenge, acquiring the goal.

Authors:  Barry M Brenner
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus.

Authors:  J Cook; D Daneman; M Spino; E Sochett; K Perlman; J W Balfe
Journal:  J Pediatr       Date:  1990-07       Impact factor: 4.406

Review 3.  The hemolytic uremic syndrome of childhood and its variants.

Authors:  B S Kaplan; W Proesmans
Journal:  Semin Hematol       Date:  1987-07       Impact factor: 3.851

4.  Long-term therapy with enalapril in patients with nephrotic-range proteinuria.

Authors:  W Proesmans; I V Wambeke; M V Dyck
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

5.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Authors:  T H Jafar; C H Schmid; M Landa; I Giatras; R Toto; G Remuzzi; G Maschio; B M Brenner; A Kamper; P Zucchelli; G Becker; A Himmelmann; K Bannister; P Landais; S Shahinfar; P E de Jong; D de Zeeuw; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  2001-07-17       Impact factor: 25.391

6.  Enalapril and prednisone in children with nephrotic-range proteinuria.

Authors:  A Delucchi; F Cano; E Rodriguez; E Wolff; X Gonzalez; M A Cumsille
Journal:  Pediatr Nephrol       Date:  2000-10       Impact factor: 3.714

7.  Angiotensin converting enzyme inhibitors and reflux nephropathy: 2-year follow-up.

Authors:  G Lama; M E Salsano; M Pedulla'; C Grassia; G Ruocco
Journal:  Pediatr Nephrol       Date:  1997-12       Impact factor: 3.714

8.  The pharmacokinetics of enalapril in children and infants with hypertension.

Authors:  T Wells; R Rippley; R Hogg; A Sakarcan; D Blowey; P Walson; B Vogt; A Delucchi; M W Lo; E Hand; D Panebianco; W Shaw; S Shahinfar
Journal:  J Clin Pharmacol       Date:  2001-10       Impact factor: 3.126

9.  Enalapril in paediatric patients with Alport syndrome: 2 years' experience.

Authors:  W Proesmans; H Knockaert; D Trouet
Journal:  Eur J Pediatr       Date:  2000-06       Impact factor: 3.183

10.  Malignant hypertension in a child with hemolytic-uremic syndrome treated with captopril.

Authors:  L Monnens; J Drayer; M De Jong
Journal:  Acta Paediatr Scand       Date:  1981-07
View more
  16 in total

1.  Chronic Kidney Disease in Children: An Indian Perspective.

Authors:  M Kanitkar
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy.

Authors:  Maria Gracia Caletti; Mabel Missoni; Clarisa Vezzani; María Grignoli; Juan Jose Piantanida; Horacio A Repetto; Ramon Exeni; Stella Maris Rasse
Journal:  Pediatr Nephrol       Date:  2011-04-30       Impact factor: 3.714

3.  Progression of chronic renal failure in children with dysplastic kidneys.

Authors:  Claudia González Celedón; María Bitsori; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2007-03-23       Impact factor: 3.714

4.  Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors.

Authors:  Mieczysław Litwin; Ryszard Grenda; Joanna Sladowska; Jolanta Antoniewicz
Journal:  Pediatr Nephrol       Date:  2006-08-15       Impact factor: 3.714

Review 5.  Clinical practice: proteinuria.

Authors:  Gema Ariceta
Journal:  Eur J Pediatr       Date:  2010-11-10       Impact factor: 3.183

Review 6.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

7.  Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.

Authors:  María Gracia Caletti; Alejandro Balestracci; Mabel Missoni; Clarisa Vezzani
Journal:  Pediatr Nephrol       Date:  2012-12-20       Impact factor: 3.714

Review 8.  Educational paper: Progression in chronic kidney disease and prevention strategies.

Authors:  Betti Schaefer; Elke Wühl
Journal:  Eur J Pediatr       Date:  2012-09-12       Impact factor: 3.183

Review 9.  Clinical practice. Today's understanding of the haemolytic uraemic syndrome.

Authors:  Johanna Scheiring; Alejandra Rosales; Lothar Bernd Zimmerhackl
Journal:  Eur J Pediatr       Date:  2009-08-26       Impact factor: 3.183

Review 10.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Authors:  Benoit Travert; Cédric Rafat; Patricia Mariani; Aurélie Cointe; Antoine Dossier; Paul Coppo; Adrien Joseph
Journal:  Toxins (Basel)       Date:  2021-04-26       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.